Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Morgan Stanley — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $282.56 (market cap $39.89B), while Morgan Stanley trades at $220.62 (market cap $350.60B). The key difference: Morgan Stanley is far larger — about 8.8× Alnylam Pharmaceuticals, Inc.'s market cap, and Morgan Stanley pays a 1.8% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MS | |
|---|---|---|
Market Cap | $39.89B | $350.60B |
Sector | Health | Financials |
52-Week High | $491.22 | $227.19 |
52-Week Low | $278.09 | $139.09 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Morgan Stanley (MS) trades at $222.28, up 0.07% on the day, with a bullish technical outlook and strong fundamental performance. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $3.43 surpassing the $3.02 estimate. Revenue growth accelerated to $66.0B in 2025, driving net income to $16.9B. The stock benefits from positive analyst sentiment, including involvement in high-profile deals like the Anthropic IPO.
The outlook remains positive given earnings momentum and a consensus price target of $225.80, though risks include volatile cash flows and rising debt levels. Investor sentiment is bolstered by strategic initiatives like AI integration in wealth management, but macroeconomic sensitivity and competitive pressures warrant monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
